CTAG1A is an inclusion criterion in 10 clinical trials for malignant solid tumor, of which 6 are open and 4 are closed. Of the trials that contain CTAG1A status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (4 open), 3 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

CTAG1A is an inclusion criterion in 9 clinical trials for synovial sarcoma, of which 5 are open and 4 are closed. Of the trials that contain CTAG1A status and synovial sarcoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

CTAG1A is an inclusion criterion in 8 clinical trials for melanoma, of which 3 are open and 5 are closed. Of the trials that contain CTAG1A status and melanoma as inclusion criteria, 6 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

CTAG1A is an inclusion criterion in 8 clinical trials for ovarian carcinoma, of which 3 are open and 5 are closed. Of the trials that contain CTAG1A status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 3 are open and 4 are closed. Of the trials that contain CTAG1A status and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (3 open) and 1 is phase 2 (0 open) [4].

CTAG1A is an inclusion criterion in 6 clinical trials for fallopian tube carcinoma, of which 2 are open and 4 are closed. Of the trials that contain CTAG1A status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 4 clinical trials for myxoid liposarcoma, of which 3 are open and 1 is closed. Of the trials that contain CTAG1A status and myxoid liposarcoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].

CTAG1A is an inclusion criterion in 4 clinical trials for primary peritoneal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain CTAG1A status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 4 clinical trials for sarcoma, of which 1 is open and 3 are closed. Of the trials that contain CTAG1A status and sarcoma as inclusion criteria, 4 are phase 1 (1 open) [4].

CTAG1A is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CTAG1A status and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) [4].

CTAG1A is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain CTAG1A status and cancer as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 3 clinical trials for esophageal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CTAG1A status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

CTAG1A is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CTAG1A status and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 1 is open and 2 are closed. Of the trials that contain CTAG1A status and multiple myeloma as inclusion criteria, 3 are phase 1 (1 open) [4].

CTAG1A is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CTAG1A status and soft tissue sarcoma as inclusion criteria, 3 are phase 1 (2 open) [4].

CTAG1A is an inclusion criterion in 2 clinical trials for bone sarcoma, of which 1 is open and 1 is closed. Of the trials that contain CTAG1A status and bone sarcoma as inclusion criteria, 2 are phase 1 (1 open) [4].

CTAG1A is an inclusion criterion in 2 clinical trials for liposarcoma, of which 0 are open and 2 are closed. Of the trials that contain CTAG1A status and liposarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

CTAG1A is an inclusion criterion in 2 clinical trials for round cell liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain CTAG1A status and round cell liposarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CTAG1A is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTAG1A status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTAG1A status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CTAG1A is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTAG1A status and lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].

CTAG1A is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CTAG1A status and lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CTAG1A is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains CTAG1A status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

CTAG1A is an inclusion criterion in 1 clinical trial for meningioma, of which 0 are open and 1 is closed. Of the trial that contains CTAG1A status and meningioma as inclusion criteria, 1 is phase 2 (0 open) [4].